BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Acadia To Seek First-Ever FDA Approval in Rett Syndrome

  The company presented an update on its Phase III LAVENDER study of trofinetide for Rett syndrome at the American Academy of Neurology’s annual meeting in Seattle.

  April 7, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Research Roundup: Alzheimer’s Research Breakthroughs Offer Potential Therapeutic Pathways

  This week, two studies provided big insights into brain changes and specific genetic sites and risk factors for Alzheimer’s disease. For those and more, continue reading.

  April 7, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  AstraZeneca Picks Up Another Oncology Asset in Quest to “Completely Replace” Standard

  AstraZeneca has penned a deal with Harbour Biomed for its bispecific antibody HBM7022, which is intended to eliminate tumors in oncological patients.

  April 7, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  FDA

  AAN Spotlight: Multiple System Atrophy, Migraine, ALS and Parkinson’s

  The American Academy of Neurology Annual Meeting (AAN) was held virtually and in-person in Seattle from April 2-7. Here’s a look at some of the highlights.

  April 7, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  ENSEM Therapeutics Banks $67 Million in Search of New Drug Targets

  Proceeds from the Series A will be used to further advance the company’s Kinetic Ensemble platform and accelerate its R&D pipeline.

  April 7, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Sanofi Closes NY Kadmon Facility in Effort to Simplify Operations

  Six months after acquiring Kadmon Holdings, pharma giant Sanofi is closing Kadmon’s New York facility. As part of the paring down, Sanofi is also laying off 25 employees at the location.

  April 7, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  A Week After Anemia Drug Rejection, Akebia Lays Off 42% of Workforce

  In a regulatory filing, the Cambridge, Massachusetts-based company indicated that it plans to “refocus its strategic priorities” and lay off 42% of its workforce.

  April 7, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  Omicron Mutates Again as Companies Race to Develop Therapeutics, Vaccines

  Global health officials are monitoring COVID-19 cases with an eye to identifying the emergence of new, potentially more deadly or more infectious variants. Read on for more details.

  April 7, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Aptinyx Suffers Defeat in Diabetic Peripheral Neuropathy as Drug Fails Endpoint

  Aptinyx therapeutic NYX-2925, intended to treat painful diabetic peripheral neuropathy failed to produce significant results. Here is why it happened.

  April 7, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  BioSpace Movers & Shakers, April 8

  Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.

  April 7, 2022

   · 

  10 min read

   · 

  Alex Keown